OverviewSuggest Edit

Merck is a healthcare manufacturer and distributor of pharmaceuticals. The Company operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. Merck offers therapeutic and preventive agents to treat cardiovascular diseases, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases.

TypePublic
Founded1891
HQKenilworth, US
Websitemerck.com
Employee Ratings3.7

Latest Updates

Employees (est.) (Dec 2018)69,000
Job Openings1,881
Revenue (FY, 2018)$42.3 B(+6%)
Share Price (Mar 2019)$81.6

Key People/Management at Merck

Kenneth Frazier

Kenneth Frazier

Chairman of the Board, CEO
Jim Scholefield

Jim Scholefield

Chief Information and Digital Officer
Robert Davis

Robert Davis

EVP, CFO
Mirian Graddick-Weir

Mirian Graddick-Weir

EVP
Julie Gerberding

Julie Gerberding

EVP
Sanat Chattopadhyay

Sanat Chattopadhyay

President, EVP
Show more

Merck Office Locations

Merck has offices in Kenilworth, Akron, Birmingham, Charleston and in 273 other locations
Kenilworth, US (HQ)
2000 Galloping Hill Rd
Albany, US
Albany, NY, USA
Albuquerque, US
Albuquerque, NM, USA
Alexandria, US
Alexandria, VA, USA
Allen, US
Allen, TX, USA
Allentown, US
Allentown, PA, USA
Show all (278)
Report incorrect company information

Merck Financials and Metrics

Merck Revenue

Embed Graph
View revenue for all periods
Merck's revenue was reported to be $42.29 b in FY, 2018
USD

Revenue (FY, 2018)

42.3b

Gross profit (FY, 2018)

28.8b

Gross profit margin (FY, 2018), %

68.1%

Net income (FY, 2018)

6.2b

Market capitalization (15-Mar-2019)

210.6b

Closing stock price (15-Mar-2019)

81.6

Cash (31-Dec-2018)

8.0b

EV

222.4b
Merck's current market capitalization is $210.6 b.
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

44.0b42.2b39.5b39.8b40.1b42.3b

Revenue growth, %

(4%)(6%)1%1%

Cost of goods sold

16.0b15.2b14.4b13.9b12.8b13.5b

Gross profit

28.1b27.1b25.1b25.9b27.3b28.8b
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

9.8b10.1b9.3b9.8b10.5b9.4b9.9b10.3b10.0b10.5b10.8b

Cost of goods sold

3.6b3.6b3.4b3.0b3.1b3.3b3.2b3.4b3.6b

Gross profit

5.7b6.3b7.1b6.4b6.9b7.1b6.9b7.0b7.2b

Gross profit Margin, %

62%64%68%68%69%68%68%67%66%
Annual
USDY, 2009Y, 2010Y, 2011Y, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

9.3b10.9b13.5b13.5b15.6b7.4b8.5b6.5b6.1b8.0b

Accounts Receivable

7.2b6.6b6.5b7.0b6.9b7.1b

Inventories

6.2b5.6b4.7b4.9b5.1b5.4b

Current Assets

35.7b33.2b29.8b30.6b24.8b25.9b
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

14.1b15.8b9.7b11.4b8.0b6.9b7.5b9.7b6.6b7.9b11.7b7.8b7.9b4.5b5.3b7.8b

Accounts Receivable

7.6b7.2b7.0b6.5b6.7b6.5b6.4b6.9b6.9b7.4b7.1b7.4b7.7b7.2b7.3b7.4b

Inventories

6.7b6.4b6.1b5.8b5.5b5.3b5.1b5.1b5.2b5.2b5.1b5.4b5.3b5.4b5.2b5.4b

Current Assets

37.8b41.2b33.6b34.7b32.9b28.3b28.6b28.8b27.9b29.4b31.5b28.2b27.9b24.1b24.1b26.8b
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

4.5b11.9b4.5b3.9b2.4b6.2b

Depreciation and Amortization

6.4b5.4b4.6b4.5b

Inventories

(365.0m)79.0m805.0m206.0m(145.0m)(911.0m)

Accounts Payable

522.0m593.0m(37.0m)278.0m254.0m230.0m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

3.7b1.7b3.8b4.6b1.6b3.5b1.1b2.3b4.5b1.6b3.5b3.5b741.0m2.5b4.4b

Depreciation and Amortization

5.0b1.8b3.5b5.1b3.2b4.8b1.6b3.1b4.3b1.2b2.4b3.5b1.1b2.4b3.4b

Cash From Operating Activities

8.6b2.4b4.7b9.0b4.9b8.2b2.2b3.8b6.7b286.0m3.6b2.4b1.2b4.5b7.3b

Cash From Investing Activities

(4.3b)(3.8b)(3.9b)(7.6b)(4.1b)(4.1b)1.7b243.0m(647.0m)3.2b2.1b2.7b(197.0m)476.0m2.1b
USDY, 2018

EV/CFO

20.4 x

EV/FCF

26.8 x

Revenue/Employee

613.0k

Financial Leverage

3.1 x
Show all financial metrics

Merck Operating Metrics

FY, 2015FY, 2016FY, 2017May, 2018Nov, 2018

Drugs Approved by FDA

1

Phase II Trials Products

14

Phase III Trials Products

24 20 20

Products

30
Show all operating metrics

Merck Acquisitions / Subsidiaries

Acquired CompanyDateDeal Size
Antelliq GroupDecember 14, 2018$2.40 b
ViralyticsFebruary 21, 2018$502 m
StayWellJuly 11, 2016
Afferent PharmaceuticalsJune 09, 2016$1.25 b
IOmet PharmaJanuary 13, 2016
cCAM BiotherapeuticsJuly 28, 2015$95 m
OncoEthixDecember 18, 2014$375 m
Cubist Pharmaceuticals, Inc.December 08, 2014$8.40 b
PreventiceSeptember 11, 2014
Peer+June 30, 2014
Show more

Merck Revenue Breakdown

Embed Graph

Merck revenue breakdown by business segment: 10.6% from Animal Health, 88.2% from Pharmaceutical and 1.1% from Other

Merck revenue breakdown by geographic segment: 43.4% from United States, 28.6% from Europe, Middle East and Africa, 10.8% from Asia Pacific, 7.8% from Japan, 5.8% from Latin America and 3.5% from Other

Report incorrect company information

Merck Online and Social Media Presence

Embed Graph
Report incorrect company information

Merck News and Updates

Merck Takes Versum Bid Hostile With Proxy Vote Proposal

Merck KGaA Takes Versum Bid Hostile With Proxy Vote Proposal

Global Human Papillomavirus (HPV) Therapeutics Market Report 2019-2023 with Market Positioning of Key Vendors - Allergan, Bausch Health, GSK, Lee's Pharmaceutical, Merck Sharp & Dohme

DUBLIN, March 8, 2019 /PRNewswire/ -- The "Global Human Papillomavirus (HPV) Therapeutics Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The human papillomavirus (HPV) therapeutics market will register a CAGR of nearly 9% by 2023. Technological advances in...

UPDATE 1-Versum, Entegris see extra merger benefits, Merck hires Goldman

Entegris and Versum Materials on Friday highlighted additional benefits from their planned all-share merger, while rival bidder Merck KGaA said it had brought in Goldman Sachs to help with its counter offer.

Merck KGaA mandates Goldman as additional advisor for Versum deal

German drugs and lab supplies group Merck KGaA has brought in Goldman Sachs as additional advisor for its unsolicited bid for Versum Materials as it seeks to break up the U.S. company's agreed merger with a rival suitor.

Global Aspergillosis Drugs Market Report 2019-2023 with Market Positioning of Key Vendors - Astellas Pharma, Gilead, Johnson & Johnson Services, Merck Sharp & Dohme, and Pfizer

DUBLIN, March 6, 2019 /PRNewswire/ -- The "Global Aspergillosis Drugs Market 2019-2023" report has been added to ResearchAndMarkets.com's offering. The aspergillosis drugs market will register a CAGR of almost 4% by 2023. Strategic alliances to trend in the market. Pharmaceuticaq...

Merck KGaA urges Versum shareholders to pipe up for rival bid

Germany's Merck KGaA called on Versum Materials Inc's shareholders to put pressure on the electronic materials maker's management to consider its jilted takeover offer.
Show more
Report incorrect company information

Merck Blogs

Merck Prices $5.0 Billion Debt Offering

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today priced a $5.0 billion public offering of four series of senior unsecured notes (…

Merck Begins Tender Offer to Acquire Immune Design

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outsta…

European Medicines Agency Adopts Positive Opinion for Merck’s KEYTRUDA® (pembrolizumab) for Six-Week Dosing Schedule Across All Current Monotherapy Indications

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the …

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion For Use in Germline BRCA-Mutated HER2-Negative Advanced Breast Cancer

Dateline City: KENILWORTH, N.J. KENILWORTH, N.J.--(BUSINESS WIRE)--AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Us…

Merck Provides Comment on U.S. Senate Committee on Finance Hearing

KENILWORTH, N.J., Feb. 26, 2019 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that today Merck Chairman and CEO Kenneth C. Frazier participated in a hearing about drug pricing held by the United States Senate Committee on Finance. In his testimony, Frazier suggest…

LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer

Dateline City: KENILWORTH, N.J. Phase 3 POLO Trial Met Its Primary Endpoint of Progression-Free Survival AstraZeneca and Merck’s LYNPARZA Is the First PARP Inhibitor to …
Show more

Merck Frequently Asked Questions

  • When was Merck founded?

    Merck was founded in 1891.

  • Who are Merck key executives?

    Merck's key executives are Kenneth Frazier, Jim Scholefield and Robert Davis.

  • How many employees does Merck have?

    Merck has 69,000 employees.

  • What is Merck revenue?

    Latest Merck annual revenue is $42.3 b.

  • What is Merck revenue per employee?

    Latest Merck revenue per employee is $613 k.

  • Who are Merck competitors?

    Competitors of Merck include Teva Pharmaceuticals, Merck and CVS.

  • Where is Merck headquarters?

    Merck headquarters is located at 2000 Galloping Hill Rd, Kenilworth.

  • Where are Merck offices?

    Merck has offices in Kenilworth, Akron, Birmingham, Charleston and in 273 other locations.

  • How many offices does Merck have?

    Merck has 278 offices.